Loss of Ras GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) inhibits the progression of ovarian cancer in coordination with ubiquitin-specific protease 10 (USP10).

Ovarian cancer (OC) is one of the most lethal gynecological malignancies. However, the molecular mechanisms underlying the development of OC remain unclear. Here, we report that loss of Ras GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) inhibits the progression of OC cells. Analysis of databases and clinical specimens showed that G3BP1 is upregulated in OC. The Kaplan-Meier plot results showed that G3BP1 is highly expressed in OC with a poor clinical outcome. Moreover, loss-of-G3BP1 suppresses the proliferation, migration, and invasion of OC cells. Protein-protein interaction network analysis and immunoprecipitation assay showed that ubiquitin-specific protease 10 (USP10) interacts with G3BP1. We next found that USP10 coordinately promotes tumor progression with G3BP1. Moreover, loss of USP10could restore the G3BP1-induced proliferation, migration, and invasion of OC cells. These data indicate that G3BP1 coordinated with USP10 to facilitate the progression of OC cells, and that G3BP1 may become a treatment target for OC.

Introduction

Ovarian cancer (OC) is one of the most lethal gynecological malignant tumors on a global scale [1]. One of the primary factors contributing to the high mortality-to-incidence ratio is the lack of characteristic clinical symptoms and pathological changes. Even though early OC has a high cure rate, the majority of women have developed into stage III/IV disease before their diagnosis, and the mortality is as high as 75% [2]. To resolve the difficulties in the treatment of OC, recent studies have deeply investigated OC at the molecular and cellular levels. However, a deeper knowledge in the pathogenesis of OC is urgently needed to be desperately needed.

Ras GTPase-activating protein SH3 domain‐binding protein 1 (G3BP1) is one of the members of Ras GAP binding protein family [3]. Structurally, it consists of an acidic region, a PXXP motif and an NTF2-like domain at the N-terminus as well as two RNA-binding motifs at the C-terminus [4,5]. This structural properties of G3BP1 underlies diversity in function. G3BP1 is widely involved in a range of physiological and pathological processes, including stress granule formation [6], RNA metabolism [7], RAS signaling pathway and cyclic GMP-AMP synthase (cGAS) [8]. Several recent studies have found that G3BP1 is significantly associated with the development of cancers, such as breast cancer [9] and gastric cancer [10]. For example, G3BP1 has an interaction with YWHAZ and further sequesters Bax into the cytoplasm, contributing to anti-apoptosis and drug resistance of gastric cancer [10]. However, its role in OC has not been well clarified.

Recently, the role of deubiquitinating enzymes in tumor has received increased attention [11]. Ubiquitin-specific protease 10 (USP10), a member of ubiquitin-specific protease family, belongs to deubiquitinating enzymes. USP10 is involved in deubiquitination activity by removing ubiquitin from ubiquitin-conjugated protein substrates [12]. USP10 is also involved in a wide range of biological functions such as environmental stress responses, tumor growth, inflammation, and cellular metabolism [13]. Emerging evidence has reported that USP10 is dysfunctional in several human cancers, such as glioblastoma, and hepatocellular carcinoma [14,15]. However, the pathophysiology of USP10 in OC need to be further clarified.

In this research, we intend to explore the potential roles and possible mechanisms of G3BP1 in OC progression. We found that G3BP1 is negatively associated with the prognosis of OC patients through Kaplan–Meier analysis. Moreover, we reported that G3BP1 played an oncogenic role in OC and produced an effect on proliferation, migration, and invasion of OC cells. Through searching for protein–protein interaction (PPI) network and Gene Expression Profiling Interactive Analysis (GEPIA) website, we found that USP10 interacted with G3BP1, and that there was a positive correlation between G3BP1 mRNA expression and USP10 mRNA expression in OC. Hence, we hypothesized that G3BP1 might facilitate OC progression by coordinating with USP10. Furthermore, we found that G3BP1 in collaboration with USP10 contributed to OC cells progression. To sum up, our data identified G3BP1-USP10 complex play an oncogenic role in OC cells.

Methods and materials

Bioinformatics analysis

The gene expression profile and clinical profile in the Cancer Genome Atlas (TCGA) were obtained from Oncomine website (www.oncomine.org). OC microarray data were obtained from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/), including GSE14407, GSE27651, and GSE10971. The UALCAN database (http://ualcan.path.uab.edu/analysis.html) was used to investigate the protein expression levels of G3BP1 in OC and the expression of G3BP1 protein in different stage of OC. The Kaplan–Meier plotter OC database (http://kmplot.com/analysis/index.php?p=service&cancer=ovarian) was used to evaluate the progression-free survival (PFS) and overall survival (OS) of OC patients based on G3BP1expression. the progression-free survival (PFS) and overall survival (OS) of OC patients based on G3BP1expression. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) network from the GeneCards website (https://www.genecards.org/) was used to determine whether a key protein was related with G3BP1. The GEPIA online database was used to analyze the mRNA expression correlation between G3BP1 and USP10 in OC tissues.

Patients and tissue samples

In this study, one control tissue array and two OC tissue arrays were created from formalin-fixed paraffin-embedded samples, which were obtained from Army Medical Center of PLA at Army Medical University from June 2009 to June 2016. The three tissue arrays included 134 serous epithelial ovarian cancers, 16 ovarian surface epithelium and 25 fallopian tube specimens. None of these OC patients received radiotherapy, chemotherapy or immunotherapy before surgery-procedures.

Immunohistochemistry (IHC) and evaluation

For IHC study, samples were dewaxed in xylene for 30 min at 65°C and rehydrated in gradient ethanol. After antigen retrieval, endogenous peroxidase was blocked with 3% hydrogen peroxide for 20 minutes at room temperature, and nonspecific binding sites were blocked with goat serum albumin. After discarding blocking solution, the tissues were incubated with G3BP1 (Abcam, UK, dilution: 1:100) at 4°C in a humidified chamber. Then, the tissues were reacted with polymer enhancer for 30 min at 37°C, followed by a biotin-labeled secondary antibody. Antibody staining was carried out by DAB kit. The final score was calculated by multiplying the staining intensity and the percentage of stained-positive cells. The staining intensity was scored according to the intensity of immunoreactivity as follows: 0, negative; 1, weak; 2, moderate; 3, strong; the percentage of stained-positive cells was scored as follows: 0, 0%; 1, 1%~25%; 2, 26%~50%; 3, 51%~75%; 4, 76%~100%. All slides were scored by two consultant clinical histopathologists in a double-blinded manner [16].

Cell culture and transfection

OC cell lines, including OVCAR3, ES2, A2780, SKOV3, and IGROV1, and the normal ovarian epithelial cell-line HOSEpiC were purchased from Chinese Academy of Medical Sciences & Peking Union Medical College (Beijing, China). The A2780 cell line was cultivated in RPMI-1640 medium (Gibco, USA) containing 10% fetal bovine serum (FBS) (AusGeneX, Australia), 100 U/mL penicillin, and 100 mg/mL streptomycin (Sigma, USA). The remaining above-described cells were cultivated in complete DMEM (Gibco, USA) medium.

The pLenti-CMV-G3BP1-GFP-Puro plasmid and the vector plasmid were purchased from PPL (Nanjing, China). Cells were transfected using jetPRIME transfection reagent (Polyplus, France). 2 µg of the plasmid was added to 200 µL of jetPRIME buffer and 2 µL of jetPRIME to 6-well plates at 60% confluence of OVCAR3 cells. Cells were processed for subsequent experiment after transfection 48 h. Targeted G3BP1-specific small-interfering RNA (siRNA), targeted USP10-specific siRNA, and the Negative control (NC) siRNA were purchased from GenePharma (Shanghai, China). OVCAR3 cells were incubated in 6-well plates at 60–80% confluence, and siRNA was used to inhibit the expression of G3BP1 or USP10 by using Lipofectamine 3000 as a transfecting agent (Thermo Fisher Scientific, USA). All siRNAs were used at a final concentration of 75 pmol and transfected into cells with 7.5 μl Lipofectamine 3000 reagent according to manufacturer’s instructions (Invitrogen). The cells were treated with siRNAs for 48 hours before subsequent experiments. The sequences for NC were as follows: UUCUCCGAACGUGUCACGUTT. The sequences for G3BP1 were as follows: CCACACCAAGATTCGCCAT and CCTGAAGAAAGACAGCAAA. The sequences for USP10 were as follows: CCAUAAAGAUUGCAGAGUUTT and CCACAUAUAUUUACAGACUTT.

Proliferation assays

The Cell Counting Kit-8 (CCK-8) assay (Bimake, USA) was used to evaluate the proliferation ability of OVCAR3 cells. After the cells were transfected, 2500 cells were plated in 96-well plates and cultured. Cells were treated with 10 μL CCK-8 reagent at the specified time and incubated at 37°C for 2 h. Absorbance at 450 nm and 630 nm was measured by enzyme labeling instrument (BioTek, USA).

Transwell assay

For the migration assay, 8.0-μm pore Transwells (Corning, USA) were put into 24-well plates. Cells at a density of 5 × 104 cells/well in 200 μL FBS-free growth media were sowed in the upper chamber. As a chemoattractant, 600 μL normal culture medium was added to the lower chamber. After incubating for 24 hours, the cells on the upper membrane were washed with PBS and wiped off with cotton swabs. The transwell inserts were fixed with 4% paraformaldehyde and stained with 0.5% crystal violet solution. Five transwell fields (magnification, ×100) were randomly selected and images were photographed under an optical microscope (Nikon, Japan). To assess the cell invasion capability, the transwell chambers were first coated with Matrigel Basement Membrane Matrix (BD Biosciences, USA). Next, the upper chamber was seeded with 8 × 104 cells/well, and culture medium was added to the lower chamber as previously described for the migration assay. After incubation, the number of cells in the lower membrane was counted [17].

RNA isolation and qRT-PCR

Cells were subjected to RNA extraction with TRIzol (Sigma, USA). cDNA was synthesized from RNA samples (1 μg) with All-in-One cDNA Synthesis Supermix (Bimake, USA). For mRNA analysis, cDNA was analyzed using ChamQ Universal SYBR qPCR Master Mix (Vazyme, China) for quantification by qRT-PCR on an Applied Biosystems QuantStudio Dx instrument (ThermoFisher, USA). The oligonucleotides used for amplification were as follows: GAPDH Forward, 5′-GACAGTCAGCCGCATCTTCT-3′; Reverse, 5′-GCGCCCAATACGACCAAATC-3′; G3BP1 Forward, 5′-CTATCCTCGGTGCTGTGGTG-3′; Reverse, 5′-GGGGGAAAAGAGTCAAATATGTCC-3′; USP10 Forward, 5′-CCTGGGCCATGATCCCATTT-3′; Reverse, 5′-TCAAGACGGGACAGAATGGC-3′.

Western blotting

Cellular proteins were extracted in cell lysis buffer and quantitated. The equal amounts of protein (50–70 µg) were subjected to 10% SDS-PAGE gel and transferred to 0.22-µm polyvinylidene difluoride membranes (Millipore, USA). The membranes were incubated for overnight at 4°C with the required primary antibodies and incubated with enzyme-labeled secondary antibody for 1 hour at room temperature. The protein bands were then captured using ECL-Plus reagent (Millipore, USA). The specific primary antibodies used for Western blotting including anti-GAPDH (Affinity Biosciences, USA, dilution: 1:1000), anti-G3BP1 (Abcam, UK, dilution: 1:1000), anti-USP10 (Abcam, UK, dilution: 1:1000).

Immunoprecipitation(IP)

1 × 107 OVCAR3 cells were gently washed twice with cold PBS. Then, cells were harvested in IP lysis buffer on ice for 30 min. The IP lysis buffer included 300 mM NaCl, 0.5% NP-40, 50 mM Tris-HCl pH 7.4, protease inhibitor cocktail (1×). Incubated the lysate supernatant with 2 µg antibody at 4°C overnight. Next, 20 µl of Protein A/G (ThermoFisher, USA) was transferred to each mixture and rotated for 2 hours at room temperature on a gentle-rotating mixer. Proteins were loaded on a 10% SDS-PAGE gel and visualized by standard procedures [18].

Statistical analysis

The association between the expression of G3BP1 and clinicopathological features was analyzed using a chi-square test. Statistical Package for the Social Sciences version 25.0 (Chicago, IL, USA) was used to conduct this analysis [16]. The other statistical analyses were performed using GraphPad Prism 7 software (GraphPad Software, USA). Data are shown as the mean ± SD. Statistical significance was determined using unpaired two-tailed Student’s t test or by one-way analysis of variance (ANOVA) among more than two groups. In each case, differences of P < 0.05 were defined as significant.

Result

In this study, we hypothesized that G3BP1 might play an important role in OC progression via combing with USP10. We first performed a bioinformatics analysis using several public clinical databases, found that G3BP1 was significantly upregulated in OC with a poor clinical prognosis. We further confirmed that G3BP1 was upregulated in OC clinical specimens. We next conducted siRNA to knockdown the expression of G3BP1 in OVCAR3 cell line. The results showed that genetic inactivation of G3BP1 significantly decreased proliferation, migration, invasion of OVCAR3 cells. To investigate the underlying mechanism, we used the PPI network analysis and IP assay confirmed that USP10 interacted with G3BP1 in OVCAR3 cells. Further, we found that USP10 coordinately promoted proliferation, migration, invasion with G3BP1 in OVCAR3 cells. These results suggested that G3BP1 might serve as a target for the treatment of OC.

G3BP1 is overexpressed in OC with a poor clinical prognosis in public databases

To analyze the expression of G3BP1 in OC, we analyzed the expression level of G3BP1 in OC and normal tissues from several public clinical databases. The TCGA OC dataset from the Oncomine website showed that G3BP1 was higher expressed in OC than in normal ovarian tissue (Figure 1a). We also analyzed G3BP1 expression in GEO dataset (GSE14407, GSE27651, GSE10971) in fallopian tube, ovarian surface epithelium and primary OC, showing that G3BP1 expression in OC was higher than that in fallopian tube or ovarian surface epithelium (Figure 1b). We also evaluated the protein expression levels of G3BP1 in UALCAN database, showing that G3BP1 was significantly higher expression in primary tumor tissues (Figure 1c). Based on UALCAN database, we further evaluated the expression of G3BP1 protein in different stage of OC. According to the clinical stage, G3BP1 expression was the highest in stage 4 (Figure 1d). Lower expression of G3BP1 protein was exhibited in stages I while higher expression in advanced stage ovarian cancer (stages III and IV) tissues. Furthermore, Kaplan–Meier analysis indicated that G3BP1 expression was significantly negatively related to the PFS and OS of the patients with OC (Figure 1e, 1f). In summary, these public database results showed that G3BP1 was overexpressed in OC with poor clinical outcome.

Figure 1.

G3BP1 is overexpressed in OC with a poor clinical prognosis in public clinical databases.

To verify these results, we performed IHC to evaluate the expression profile of G3BP1 in clinical samples by three tissue chips, which included 134 serous epithelial ovarian cancers, 16 ovarian surface epithelium, and 25 fallopian tube specimens. IHC analysis illustrated that G3BP1 was primarily located in the cytoplasm of OC tissues and manifested as light brown and brown particles (Figure 2a). Compared to fallopian tube specimen or ovarian surface epithelium, most OC samples showed higher enrichment of G3BP1 (Figure 2b). To explore the possible correlations between G3BP1 expression and clinical features of OC, we further analyzed the clinicopathological parameters of 134 OC patients based on the H score of G3BP1 expression. However, no significant association was observed between G3BP1 expression and patient age, FIGO stage, tumor differentiation, omentum metastasis, cytoreduction or response to initial chemotherapy (Tab. S1). We also performed Western blotting to detect the G3BP1 expression levels in normal ovarian epithelial HOSEpiC cells and several OC cell lines. The Western blotting results revealed that the expression of G3BP1 was upregulated in OC cell lines compared with normal ovarian epithelial cells (Figure 2c). Collectively, both the public database and our IHC result showed that G3BP1 was highly expressed in OC.

Figure 2.

The G3BP1 protein expression in OC tissues and cell lines.

To determine the functional roles of G3BP1 in cancer progression, we first performed a loss-of-function study by means of siRNA. Based on the result in Figure 2c, the OVCAR3 cells own the highest expression level of G3BP1 among 5 OC cell lines. Therefore, we chose this cell line for the rest in vitro experiments. We designed two siRNAs to silence G3BP1 expression in OVCAR3 cells. Both the mRNA and protein expression levels of G3BP1 were dramatically knocked down by si-RNAs (Figure 3a, 3b). The CCK-8 assay indicated that loss-of-G3BP1 significantly suppressed the cell growth of OVCAR3 cells (Figure 3c). The transwell assay illustrated that the migration and invasion ability of OVCAR3 cells was suppressed upon si-G3BP1 treatment (Figure 3d). These results suggested that knockdown of G3BP1 suppressed the progression of OC.

Figure 3.

Knockdown of G3BP1 suppresses the progression of OC cells.

To explore the mechanisms by which G3BP1 promotes the progression of OC, we used the STRING network from the GeneCards website to determine whether a key protein was related with G3BP1. Analysis of G3BP1 through the PPI network showed 25 correlated proteins (Figure 4a). The top 5 STRING interactants were G3BP2, USP10, RIOK2, EIF2A, NUFIP2 (Figure 4b). Correlation analysis of these five targets were performed from PPI network, and the results showed that the top correlative target was USP10 (Figure 4c). To assess whether G3BP1 interacts with USP10 in OC or not, we used an IP assay to verify this interaction. The results suggested that G3BP1 bound well to USP10 at endogenous level (Figure 4d, 4e). In addition, we used GEPIA database to evaluate the correlation between G3BP1 mRNA expression and USP10 mRNA expression. The results showed that there was a positive correlation in OC (figure 4f). In summary, these results imply that G3BP1 interacts with USP10 in OC cells.

Figure 4.

G3BP1 interacts with USP10 in OC cells.

Knockdown of USP10 suppresses the progression of OC cells

To determine the role of USP10 in OC progression, we investigated cell proliferation after disruption of USP10 by siRNAs (knockdown efficiency is shown in Figure 5a, 5b). The CCK-8 assay demonstrated that knockdown of USP10 in OVCAR3 cells reduced cell proliferation compared with the control group (Figure 5c). To test whether reduced USP10 also negatively affected tumor metastasis in vitro, we used transwell assay to evaluate cell migration and invasion levels. As shown in Figure 5d, cell migration and invasion ability also declined upon knockdown of USP10. These results suggest that genetic inactivation of USP10 inhibits OVCAR3 cells proliferation, migration and invasion.

Figure 5.

Knockdown of the USP10 inhibits OC cell progression.

Knockdown of G3BP1&USP10 inhibits OC cell progression

Next, we sought to determine the coordination relationship of G3BP1 and USP10 in the role of OC progression, we employed the concomitant knockdown of G3BP1 and USP10. Western blotting assay was used to examine the expression of the G3BP1&USP10 knockdown in OVCAR3 cell line (Figure 6a). A more noticeable reduction in cell growth was observed upon the downregulation of both G3BP1 and USP10 than with the downregulation of either G3BP1 or USP10 alone (Figure 6b). Moreover, cell migration and invasion ability also declined upon knockdown of G3BP1 coupled with USP10, relative to knockdown of either alone (Figure 6c). In summary, these results suggest that G3BP1 and USP10 work coordinately in OC cells.

Figure 6.

Knockdown of the G3BP1&USP10 inhibits OC cell progression.

Overexpression of G3BP1 promotes the progression of OC cells in a USP10-dependent manner

As we found that G3BP1 combined with USP10 in OC cells, we further evaluated the role of G3BP1-USP10 complex of in OVCAR3 cells. The G3BP1-overexpressing OVCAR3 cells were transfected with si-USP10, then Western blotting was performed to assess the expression levels of G3BP1 and USP10 (Figure 7a). The CCK-8 assay showed that overexpression of G3BP1 promoted cell growth, whereas knockdown of USP10 reversed this effect, indicating that a reduction in USP10 expression ameliorated the G3BP1-mediated proliferation of cell growth (Figure 7b). Consistent with this finding, the promotion of cell migration and invasion by G3BP1 overexpression was reversed after USP10 was downregulated (Figure 7c). Together, these results suggest G3BP1 can promote the progression of OC in a USP10-dependent manner.

Figure 7.

Overexpression of G3BP1 promotes OC cell progression in a USP10-dependent manner.

Discussion

We uncovered that G3BP1 is necessary for OC progression and is associated with a poor clinical outcome, which was verified by analyzing bioinformatics data, clinical samples and by loss-of-function assays. Mechanistically, G3BP1 forms a complex with USP10 in the progression of OC. In return, we found that the G3BP1-USP10 complex can contribute to the development of OC cells. Remarkably, these results showed that G3BP1 might be a treatment target for OC.

On the whole, G3BP1 is essential for regulating several basic cellular processes. One of the most widespread function is the formation of stress particles [19]. In addition, G3BP1 has been identified for its roles in the DNA-triggered cGAS/STING pathway by promoting the DNA binding and activation of cGAS . G3BP1 also has been reported to switch phase separation [6]. In recent years, studies concentrating on the roles of G3BP1 in cancer have been gradually reported. G3BP1 has been previously established to play a significant oncogenic role in the progression of cancers [7,9,10,20]. For example, a study indicated that G3BP1 has an interaction with GSK-3β, contributing to promote breast cancer proliferation in vitro [9]. Another previous study showed that G3BP1 can act as the lncRNA SPOCD1-AS target protein in OC, resulting in a mesothelial-to-mesenchymal transition manner of mesothelial cells. Additionally, the mesothelial-to-mesenchymal transition can be inhibited by targeting the RRM domain and F380/F382 residues of G3BP1 [20]. In our study, we analyzed a large number of clinical samples, several databases and performed functional experiments in vitro. We demonstrate that G3BP1 plays an oncogenic role in the development of OC. However, when seeking for further clinical relevance in our own clinical OC samples, we do not find association of G3BP1 with any clinicopathological characteristics. This result is not consistent with several databases results. Therefore, we believe that the sample size in this study is still relatively small and the statistical power is limited. This topic should be expanded with large sample size in the next step of study.

In specific biological processes, several protein functions are often exerted by interacting with each other, instead of working independently [21]. With the quick advancements in high-throughput sequencing techniques and experimental technologies, researchers can identify big amounts of PPI data and describe very complex interactome datasets [22]. Growing studies underscores the importance of protein interactome in a variety of disease researches [23-25]. Taken together, an in-depth study of the function of PPI is helpful to discover new potential therapeutic targets. We utilized PPI network analysis and IP assay to confirm the interaction between G3BP1 and USP10 in OC. USP10, a vital member of the deubiquitinase family, involves in several biological processes, including ubiquitin recycling [26], ribosome recycling [27,28] and stress granule formation [29]. USP10 also participates in the development of cancer in a context-dependent manner. Some studies have found that USP10 acts as an oncogene in glioblastoma multiforme and breast cancer [15,30], while other studies have shown that USP10 plays tumor-suppressive roles in colon cancer and gastric carcinoma [31,32]. In OC, it is recently reported that the expression of USP10 is evaluated in clinical samples, and that loss-of-USP10 suppresses OC xenograft growth [33]. But there is a report showing that USP10 is downregulated in OC tissues compared to normal epithelium tissues. USP10 is also associated with a favorable clinical prognosis in OC [34]. These results suggest that USP10 has a dual effect on OC. In this study, we found that USP10 could facilitate the progression of OC. Our data feed the ongoing debate regarding whether USP10 exerts an oncogenic role or a tumor suppressor role in OC.

Our findings showed that loss of G3BP1 significantly inhibits the progression of OC. We next found that USP10 is a potent regulator of G3BP1 expression in OC cells, and confirmed that G3BP1 bound well to USP10 at endogenous level in OC cells. We found that knockdown of G3BP1 inhibits the expression of USP10 mRNA (Fig. S1A), suggesting that it might affect the expression of USP10 at the transcript level. Interesting, G3BP1 knockdown do not influence the USP10 protein expression (Fig. S1B). We speculate that USP10 is a long half-life protein, G3BP1 mRNA degradation in very short time might not affect the protein level of USP10. As we all know, the protein concentration is determined by the balance between protein synthesis and degradation. It seems reasonable to speculate that if G3BP1 represses the production of USP10 protein together with preventing USP10 protein degradation, the expression USP10 might not change significantly. G3BP1 has been reported to suppress p62&USP10 complex ubiquitination [35], indicating that G3BP1 may regulate protein expression by inhibiting USP10 ubiquitination. We also found that USP10 knockdown decreased mRNA and protein levels of G3BP1 (Fig. S1C, 1D). USP10 is known to deubiquitylate its target proteins, mainly to enhance their stabilities. For example, USP10 regulates p53 localization and stability by deubiquitinating p53 in clear cell carcinomas [36]. However, G3BP1 is not the substrate for USP10. It is the G3BP1-USP10 complex that is a substrate of USP10, which could deubiquitylate the complex to promote its function [37]. Recently, the potential function of the G3BP1-USP10 has also been gradually revealed. G3BP1–Caprin1–USP10 complexes are likely to be involved in stress granule condensation. The G3BP1-Caprin1 complex can assemble mRNPs into SGs by escorting them through a demixing phase transition, whereas the G3BP1-USP10 complex reverses this process. This observation suggests the central role of G3BP1–Caprin1–USP10 complexes on SG formation process [29]. Some scholars believe that the G3BP1-family-USP10 complex can participate in mRNA degradation, and release the stalled and modified ribosomes, resulting in polysomes ribosome-associated quality control and stalled ribosome dissociation [27]. These findings indicate that the effect of G3BP1-USP10 complex is all-round. In summary, the G3BP1-USP10 complex have been widely implicated in a wide spectrum of physiological processes such as ubiquitination modification and stress granules formation.

In our research, we showed that knockdown G3BP1 plus USP10 could further inhibit the progression of OC in vitro. Our study indicates that the G3BP1-USP10 complex is important for tumor progression. Overall, the G3BP1-USP10 complex may modulate biological processes in several ways: (i) the G3BP1-Caprin1-USP10 complex is involved in stress granule condensation and binds with 40S subunits; (ii) the deubiquitinase complex inhibits the ubiquitination of ribosome 40S subunits via lysosomal degradation at the translational level; (ii i) G3BP1 affects the expression and function of target proteins through changing ubiquitination modification of USP10.

Our findings suggest that the G3BP1 might be a promising target for OC therapy and the G3BP1-USP10 complex play vital roles in OC. Although our study implicate the G3BP1-USP10 complex promote the progression of OC, future in-depth investigations are strongly recommended to explore the underlying mechanisms. Moreover, further research involving animal studies and clinical specimens is needed to investigate the precise role of G3BP1-USP10 in OC.

Conclusion

In conclusion, we used a combination of computational, biochemical, and functional approaches to demonstrated G3BP1 increased in OC tissues and cell lines, and high G3BP1 expression facilitated malignant biological properties of OC cells. It is the first time for our research to reveal that G3BP1 silencing can suppress the proliferation, migration, and invasion capabilities of OC cells. Also, we identified the role of G3BP1-USP10 complex in OC development. These findings offer a novel therapeutic target for OC treatment.